Table 1.

Characteristics of study population by age group. Data are mean (s.d.) unless otherwise stated.

	Age group
	Early (n = 40)	Intermediate (n = 42)	Late (n = 90)
Age at GH treatment start (years)	6.4 (1.8)	9.7 (0.9)	12.3 (1.4)
Male, n (%)	28 (70.0)	24 (57.1)	62 (68.9)
Age at puberty (years)	12.4 (1.5)a	12.2 (1.2)b	13.5 (1.6)c
Prepubertal treatment period (years)	6.0 (2.6)d	2.4 (1.0)e	1.3 (1.1)f
HSDS at baseline	−3.2 (0.9)	−2.7 (0.8)	−2.8 (1.0)
Bone age at start of treatment (years)	5.3 (2.5)g	8.1 (1.0)h	10.0 (1.8)i
Bone age/chronological age at start of treatment	0.8 (0.3)g	0.9 (0.1)h	0.8 (0.2)i
Target (mid-parental) HSDS	−0.8 (1.1)	−1.2 (0.9)j	−0.7 (0.8)k
Age at NAH (years)	16.6 (1.3)	16.4 (1.3)	17.4 (1.3)
Age at last presentation (years)	17.7 (1.7)	17.0 (1.3)	17.9 (1.2)
GH dose at baseline (µg/kg/day)	33.8 (13.2)j	28.6 (7.5)l	30.1 (8.3)m
Duration of GH treatment from baseline to NAH (years)	10.2 (2.1)	6.5 (1.2)	5.0 (0.8)
GH average dose during treatment period (μg/kg/day)	32.7 (5.6)	32.9 (7.0)n	31.6 (6.5)
NAH SDS	−1.0 (1.2)	−1.5 (0.9)	−1.3 (1.1)
Difference between NAH and target (mid-parental) height SDS	−0.2 (0.9)	−0.2 (1.0)j	−0.6 (1.2)k
∆HSDS	2.3 (1.3)	1.4 (0.9)	1.5 (0.9)
Mean GH stimulation test peak value (ng/mL)	4.6 (2.4)	5.7 (2.4)	4.8 (2.5)

Early (girls aged <8 years; boys aged <9 years), intermediate (girls aged 8–10 years; boys aged 9–11 years) or late (girls aged >10 years; boys aged >11 years).

^an = 19, ^bn = 26, ^cn = 50, ^dn = 24, ^en = 29, ^fn = 56, ^gn = 11, ^hn = 12, ⁱn = 25, ^jn = 39, ^kn = 86, ^ln = 40, ^mn = 83, ⁿn = 41.

GH, growth hormone; HSDS, height standard deviation score; ∆HSDS, change in height standard deviation score from baseline to NAH; NAH, near adult height; s.d., standard deviation; SDS, standard deviation score.